G G Di Costanzo
Overview
Explore the profile of G G Di Costanzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, et al.
ESMO Open
. 2022 Oct;
7(6):100591.
PMID: 36208496
Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials And Methods: We carried out a retrospective analysis of prospectively collected data...
2.
Rapposelli I, Shimose S, Kumada T, Okamura S, Hiraoka A, Di Costanzo G, et al.
ESMO Open
. 2021 Jun;
6(4):100190.
PMID: 34144271
Background: After the advent of new treatment options for advanced hepatocellular carcinoma (HCC), the identification of prognostic factors is crucial for the selection of the most appropriate therapy for each...
3.
Buonomo A, Viceconte G, Scotto R, De Angelis M, Tozza S, Manganelli F, et al.
Infect Dis (Lond)
. 2019 Nov;
52(3):216-218.
PMID: 31766959
No abstract available.
4.
Ng C, Di Costanzo G, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G, et al.
Ann Oncol
. 2018 Mar;
29(5):1286-1291.
PMID: 29509837
Background: Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the...
5.
Di Costanzo G, Lanza A, Picciotto F, Imparato M, Migliaccio C, De Luca M, et al.
Am J Transplant
. 2012 Nov;
13(2):348-52.
PMID: 23137160
Life-long hepatitis B immunoglobulin (HBIG) administration is a main component of prophylactic strategy to prevent hepatitis B virus (HBV) reinfection after liver transplantation (LT). Long-term effects of HBIG treatment are...
6.
Perrella A, Arenga G, Pisaniello D, Rampone B, Di Costanzo G, Atripaldi L, et al.
Transplant Proc
. 2009 Jun;
41(5):1761-6.
PMID: 19545723
Background/aim: Factors involved in hepatitis C virus (HCV) recurrence versus acute cellular rejection are not fully understood. The aim of the present study was to investigate whether patients with recurrence...
7.
Di Costanzo G, Ragozzino A, Niola R, Maglione F, Ascione A
Gut
. 2005 Dec;
55(1):53, 73.
PMID: 16344575
No abstract available.
8.
Ascione A, De Luca M, Canestrini C, Di Costanzo G, Raimondo G, Longo G, et al.
Ital J Gastroenterol Hepatol
. 1998 Dec;
30(5):517-23.
PMID: 9836109
Background/aims: The long-term response to alpha-Interferon in HCV-related chronic liver diseases is disappointing. A randomized controlled trial was conducted to investigate: 1) if doubling the standard regimen of 3 MU...
9.
Di Costanzo G, Ascione A, Lanza A, De Luca M, Bracco A, Lojodice D, et al.
Ital J Gastroenterol
. 1996 Apr;
28(3):140-6.
PMID: 8789824
The response rate to interferon in HCV chronic liver disease is insufficient to date and the causes of this failure are not fully understood. Hepatic fibrosis hinders the blood-hepatocyte exchange...
10.
Di Costanzo G, Ascione A, Galeota Lanza A, Utech W, Capobianco G, Vacca C
J Hepatol
. 1995 Sep;
23(3):359-60.
PMID: 8551006
No abstract available.